



Clear Direction With MEDRAD® Salient

The MEDRAD® Salient Injection System has been engineered to combine innovation and mobility in order to bring simplicity and reliability to your suite.





Simplicity

- > Intuitive, icon-driven interface
- Flexible workflow and software architecture
- > Single-action syringe loading
- Minimal installation with battery operation for total mobility



Reliability

- Dependable, reproducible flow rates and pressures that can consistently deliver injection protocols
- Provides a maximum pressure up to 300 psi and up to 10 mL/s
- Power injection enables accurate and repeatable contrast administration¹⁻⁴

"The Salient is an integral part of our Contrast Mammography procedure. Our workflow is efficient as we can be drawing up the contrast into the syringe with the autofill function while the patient is being cannulated by the nursing staff."

CEM Radiographer Australia

Salient Injector User Experience Interview (2023)





Your Partner for Contrast-Enhanced Mammography⁵⁻⁷

Salient can support a wide range of procedures, including contrast-enhanced mammography (CEM).

Several research studies demonstrate⁵⁻⁷ the efficacy and importance of CEM in breast cancer detection and management. CEM can facilitate early diagnosis of breast cancer, which is crucial to providing optimal treatment options. Breast cancer is the most commonly diagnosed cancer globally,⁷ but with early detection and intervention, it is also one of the most treatable.⁸





Main Features and Benefits





The straightforward design of Salient offers flexibility for your daily operations.

- Cordless configuration:
 Helps keep floor free of cords
 for a safer clinical environment
- Compact design:
 Enhances mobility
 Enables easy transport and storage
- Extensive Applications: Easily performs CEM injection protocols*
- Customised protocols:
 Allows customised protocols up to six phases
 Saves up to 20 customised injection protocols



Additional Tools for Enhanced Efficiency

Salient can be further tailored with the following accessories and features:

- Protocol Assistant Tool (PAT)
- Assurance: Salient has indications for x-ray diagnostic procedures, including CEM.



Control room monitor with the Protocol Assistant Tool (PAT)


^{*}Example protocol for CEM. 1.5mls/kg at 2-4 mls/sec.





Bayer Is Your Partner


MEDRAD® injectors can support you in achieving diagnostic image quality for your patients and workflow efficiency in your CEM procedures.



Example protocol for fictional patient.

- Our Service and Application Specialists provide quality service and solutions to meet your clinical, financial, and operational needs.
- To learn more about MEDRAD® Salient Single and other Bayer products, please speak to your local Bayer representative.





MEDRAD® Salient Technical Specifications

Functional

Maximum pressure	300 psi	
Flow rate	0.1 to 10 mL/s	
Maximum volume	190 mL	
Multi-phase protocols	Up to six phases. Storage for 20 different named protocol	
Manual fill rate	Up to 10 mL/s	
Auto fill rate	Up to 10 mL/s	

Controls

Base	Line power, IEC inlet, on/off switch	
Head	5.7" LCD touch screen, arm button, on/off soft switch	
Infrared remote control	Inject start/stop	

Mechanical

Weight	25 kg (Single)	
Height	1315 mm	
Floor area	500 mm x 500 mm	
No. of wheels	4 casters, all individually locking	

Electrical

100 – 230 VAC
50/60 Hz
Dual batteries, sealed lead acid
Simultaneous operation and battery charging
37°C +/- 4°C, 5W

Ordering Details

PART NAME	PART NO.	
Salient Single Injector With Remote Control Unit	DC009SW	
Salient Dual Injector With Remote Control Unit	DC009DW	
Connector Tubing Single (box of 50)	ZY5151	
Connector Tubing for Dual (box of 50)	ZY5152	
Syringe With Fill Spike (box of 50)	ZY6323	
Syringe With Fill Spike, Single LPCT (box of 50)	ZY6324	
Syringe With Quick Fill Tube, Single LPCT (box of 50)	ZY6325	

References:

- 1. Endrikat J, Barbati R, Scarpa M, Jost G, Ned A. Accuracy and Repeatability of Automated Injector Versus Manual Administration of an MRI Contrast Agent Results of a Laboratory Study. *Invest Radiol.* Jan 2018;53(1):1–5.
- 2. McDermott M, Kemper C, Barone W, Jost G, Endrikat J. Impact of CT Injector Technology and Contrast Media Viscosity on Vascular Enhancement: Evaluation in a Circulation Phantom. *Br J Radiol*. May 1 2020;93(1109):20190868.
- 3. Jost G, Endrikat J, Pietsch H. The Impact of Injector-Based Contrast Agent Administration on Bolus Shape and Magnetic Resonance Angiography Image Quality. *Magn Reson Insights*. 2017;10:1178623x17705894.
- 4. Bayer. Salient Operation Manual. 2019.
- 5. Cozzi A, Magni V, Zanardo M, Schiaffino S, Sardanelli F. Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance. Radiology. 2022;302(3):568–581. doi:10.1148/radiol.211412.
- 6. Bicchierai G, Tonelli P, Piacenti A, De Benedetto D, Boeri C, Vanzi E, Bianchi S, Cirone D, Kaur Gill M, Miele V, Nori J. Evaluation of contrast-enhanced digital mammography (CEDM) in the preoperative staging of breast cancer: Large-scale single-center experience. Breast J. 2020;26(7):1276–1283. doi:10.1111/tbj.13766.
- 7. Houben IPL, Van de Voorde P, Jeukens CRLPN, Wildberger JE, Kooreman LF, Smidt ML, Lobbes MBI. Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. *Eur J Radiol.* 2017;94:31–37. doi:10.1016/j. ejrad.2017.07.004-6.
- 8. WHO. Current and future burden of breast cancer: global statistics for 2020 and 2040. Accessed November 2022. https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040/#:~:text=Breast%20cancer%20is%20the%20most,between%20countries%20and%20world%20regions.
- 9. Chang L, Weiner LS, Hartman SJ, Horvath S, Jeste D, Mischel PS, Kado DM. Breast cancer treatment and its effects on aging. *J Geriatr Oncol.* 2019;10(2):346–355. doi:10.1016/j.jgo.2018.07.010.



The patient data that appears in this document is fictitious protected health information (PHI) and/or actual PHI from which all personally identifiable information (PII) has been removed or otherwise anonymised. No personally identifiable information is shown.

Bayer, the Bayer Cross, MEDRAD Salient, MEDRAD, and Salient are trademarks owned by and/or registered to Bayer in the US and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2025 Bayer. This material may not be reproduced, displayed, modified, or distributed without the express prior written consent of Bayer.



Radiology

Bayer Australia Ltd 875 Pacific Highway Pymble NSW 2073 Australia

Phone: 1800 008 757 ABN: 22 000 138 714



Manufacturer

Imaxeon Pty Ltd Unit 1, 38 – 46 South Street Rydalmere, NSW 2116 Australia

Phone: 02 8845 4999 Fax: 02 8845 4936

Customer Service: 1800 633 723

Australian Sponsor

Imaxeon Pty Ltd Unit 1, 38 – 46 South Street Rydalmere, NSW 2116 Australia

Phone: 02 8845 4999 Fax: 02 8845 4936

Customer Service: 1800 633 723

More information on radiology.bayer.com.au

PP-M-SAL-AU-0014-2 Date of preparation: August 2025